#descovy

[munarloth]

there's a certain kind of environmental storytelling to hulu playing a shitload of ads for alcohol and prep over what we do in the shadows

[mcatmemoranda]

I have a pt in Descovy for PrEP. Their website has all the info you should know about how to monitor for adverse effects on this medication.

What is DESCOVY for PrEP?

DESCOVY for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex.

DESCOVY for PrEP is not for everyone:

It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness has not been studied.

You must be HIV-negative before and while taking DESCOVY for PrEP. Talk to a healthcare provider to see if DESCOVY for PrEP may be an option for you.

Important Safety Information

What is the most important information I should know about DESCOVY for PrEP?

Before and while taking DESCOVY for PrEP:

You must be HIV-negative before you start and while taking DESCOVY for PrEP. You must get tested for HIV-1 immediately before and at least every 3 months while taking DESCOVY. If you think you were exposed to HIV-1, tell your healthcare provider right away. They may want to do more tests to confirm that you are still HIV-negative.

Many HIV-1 tests can miss HIV-1 infection in a person who has recently become infected. Tell your healthcare provider if you had a flu-like illness within the last month before starting or while taking DESCOVY. Symptoms of new HIV-1 infection include tiredness, fever, joint or muscle aches, headache, sore throat, vomiting, diarrhea, rash, night sweats, and/or enlarged lymph nodes in the neck or groin.

DESCOVY by itself is not a complete treatment for HIV-1. Do not take DESCOVY for PrEP unless you are confirmed to be HIV-1 negative.

DESCOVY does not prevent other sexually transmitted infections (STIs). Practice safer sex by using a latex or polyurethane condom to reduce the risk of getting STIs.

To further help reduce your risk of getting HIV-1:

Do not miss any doses of DESCOVY. Missing doses may increase your risk of getting HIV-1.

Know your HIV status and the HIV status of your partners. If your partner is living with HIV, your risk of getting HIV is lower if your partner consistently takes HIV treatment every day.

Get tested for other STIs. Some STIs make it easier for HIV-1 to infect you.

Talk to your healthcare provider about all the ways to help reduce HIV risk.

DESCOVY can cause serious side effects:

Worsening of hepatitis B (HBV) infection. Your healthcare provider will test you for HBV. If you have HBV and stop taking DESCOVY, your HBV may suddenly get worse. Do not stop taking DESCOVY without first talking to your healthcare provider, as they will need to check your health or give you HBV medicine.

Who should not take DESCOVY for PrEP?

Do not take DESCOVY for PrEP if you:

Already have HIV-1 or if you do not know your HIV-1 status. If you have HIV-1, you need to take other medicines with DESCOVY to treat HIV-1. If you have HIV-1 and take only DESCOVY, your HIV-1 may become harder to treat now and in the future.

What are the other possible side effects of DESCOVY for PrEP?

Serious side effects of DESCOVY may also include:

Kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys before and during treatment with DESCOVY. If you develop kidney problems, your healthcare provider may tell you to stop taking DESCOVY.

Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.

Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark "tea-colored" urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

Common side effects in people taking DESCOVY for PrEP are diarrhea, nausea, headache, fatigue, and stomach pain. Tell your healthcare provider if you have any side effects that bother you or do not go away.

What should I tell my healthcare provider before taking DESCOVY for PrEP? All your health problems. Be sure to tell your healthcare provider if you have or have had any kidney or liver problems, including hepatitis. All the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. DESCOVY may interact with other medicines. Keep a list of all your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.v You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

What is DESCOVY for PrEP?

DESCOVY for PrEP (pre-exposure prophylaxis) is a once-daily prescription medicine for adults and adolescents at risk of HIV. It helps lower the chances of getting HIV through sex.

DESCOVY for PrEP is not for everyone:

It is not for use in people assigned female at birth who are at risk of getting HIV from vaginal sex, because its effectiveness has not been studied.

You must be HIV-negative before and while taking DESCOVY for PrEP. Talk to a healthcare provider to see if DESCOVY for PrEP may be an option for you.

[fresherfriut]

[virginpornstar]

Cancel Culture can come for anyone, and this time is came for me. Expressing my preferences for being with a man that doesn't have HIV made all of black gay Twitter come for me. I've received thousands of hateful messages in the past week, but thankfully I can still find the humor in this situation. There's so much hilarious irony in the gay community bullying a gay man over expressing what type of men he wants to be with.

Branden's Boy Problems Episode 131: Cancelled

Follow me on all social media platforms!

[reasonsforhope]

"A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Physician-scientist Linda-Gail Bekker, principal investigator for the South African part of the study, tells Nadine Dreyer what makes this breakthough so significant and what to expect next.

Tell us about the trial and what it set out to achieve

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs.

Lenacapavir (Len LA) is a fusion capside inhibitor. It interferes with the HIV capsid, a protein shell that protects HIV’s genetic material and enzymes needed for replication. It is administered just under the skin, once every six months.

The randomised controlled trial, sponsored by the drug developers Gilead Sciences, tested several things.

The first was whether a six-monthly injection of lenacapavir was safe and would provide better protection against HIV infection as PrEP for women between the ages of 16 and 25 years than Truvada F/TDF, a daily PrEP pill in wide use that has been available for more than a decade.

Secondly, the trial also tested whether Descovy F/TAF, a newer daily pill, was as effective as F/TDF...

The trial had three arms. Young women were randomly assigned to one of the arms in a 2:2:1 ratio (Len LA: F/TAF oral: F/TDF oral) in a double blinded fashion. This means neither the participants nor the researchers knew which treatment participants were receiving until the clinical trial was over.

In eastern and southern Africa, young women are the population who bear the brunt of new HIV infections. They also find a daily PrEP regimen challenging to maintain, for a number of social and structural reasons.

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency.

By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus...

What is the significance of these trials?

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV.

There were 1.3 million new HIV infections globally in the past year. Although that’s fewer than the 2 million infections seen in 2010, it is clear that at this rate we are not going to meet the HIV new infection target that UNAIDS set for 2025 (fewer than 500,000 globally) or potentially even the goal to end Aids by 2030...

For young people, the daily decision to take a pill or use a condom or take a pill at the time of sexual intercourse can be very challenging.

HIV scientists and activists hope that young people may find that having to make this “prevention decision” only twice a year may reduce unpredictability and barriers.

For a young woman who struggles to get to an appointment at a clinic in a town or who can’t keep pills without facing stigma or violence, an injection just twice a year is the option that could keep her free of HIV.

What happens now?

The plan is that the Purpose 1 trial will go on but now in an “open label” phase. This means that study participants will be “unblinded”: they will be told whether they have been in the “injectable” or oral TDF or oral TAF groups.

They will be offered the choice of PrEP they would prefer as the trial continues.

A sister trial is also under way: Purpose 2 is being conducted in a number of regions including some sites in Africa among cisgender men, and transgender and nonbinary people who have sex with men.

It’s important to conduct trials among different groups because we have seen differences in effectiveness. Whether the sex is anal or vaginal is important and may have an impact on effectiveness.

How long until the drug is rolled out?

We have read in a Gilead Sciences press statement that within the next couple of months [from July 2024] the company will submit the dossier with all the results to a number of country regulators, particularly the Ugandan and South African regulators.

The World Health Organization will also review the data and may issue recommendations.

We hope then that this new drug will be adopted into WHO and country guidelines.

We also hope we may begin to see the drug being tested in more studies to understand better how to incorporate it into real world settings.

Price is a critical factor to ensure access and distribution in the public sector where it is badly needed.

Gilead Sciences has said it will offer licences to companies that make generic drugs, which is another critical way to get prices down.

In an ideal world, governments will be able to purchase this affordably and it will be offered to all who want it and need protection against HIV."

-via The Conversation, July 3, 2024

[warningsine]

A large clinical trial in South Africa and Uganda has shown that a twice-yearly injection of a new pre-exposure prophylaxis drug gives young women total protection from HIV infection.

The trial tested whether the six-month injection of lenacapavir would provide better protection against HIV infection than two other drugs, both daily pills. All three medications are pre-exposure prophylaxis (or PrEP) drugs.

Physician-scientist Linda-Gail Bekker, principal investigator for the South African part of the study, tells Nadine Dreyer what makes this breakthough so significant and what to expect next.

Tell us about the trial and what it set out to achieve

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs.

Lenacapavir (Len LA) is a fusion capside inhibitor. It interferes with the HIV capsid, a protein shell that protects HIV’s genetic material and enzymes needed for replication. It is administered just under the skin, once every six months.

The randomised controlled trial, sponsored by the drug developers Gilead Sciences, tested several things.

The first was whether a six-monthly injection of lenacapavir was safe and would provide better protection against HIV infection as PrEP for women between the ages of 16 and 25 years than Truvada F/TDF, a daily PrEP pill in wide use that has been available for more than a decade.

Secondly, the trial also tested whether Descovy F/TAF, a newer daily pill, was as effective as F/TDF. The newer F/TAF has superior pharmacokinetic properties to F/TDF. Pharmacokinetic refers to the movement of a drug into, through, and out of the body. F/TAF is a smaller pill and is in use among men and transgender women in high-income countries.

The trial had three arms. Young women were randomly assigned to one of the arms in a 2:2:1 ratio (Len LA: F/TAF oral: F/TDF oral) in a double blinded fashion. This means neither the participants nor the researchers knew which treatment participants were receiving until the clinical trial was over.

In eastern and southern Africa, young women are the population who bear the brunt of new HIV infections. They also find a daily PrEP regimen challenging to maintain, for a number of social and structural reasons.

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency.

By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus.

The results at a recent independent data safety monitoring board review led to the recommendation that the trial’s “blinded” phase should be stopped and all participants should be offered a choice of PrEP.

This board is an independent committee of experts who are put in place at the start of a clinical trial. They see the unblinded data at stipulated times during the trial to monitor progress and safety. They ensure that a trial does not continue if there is harm or a clear benefit in one arm over others.

What is the significance of these trials?

This breakthrough gives great hope that we have a proven, highly effective prevention tool to protect people from HIV.

There were 1.3 million new HIV infections globally in the past year. Although that’s fewer than the 2 million infections seen in 2010, it is clear that at this rate we are not going to meet the HIV new infection target that UNAIDS set for 2025 (fewer than 500,000 globally) or potentially even the goal to end Aids by 2030.

PrEP is not the only prevention tool.

PrEP should be provided alongside HIV self-testing, access to condoms, screening and treatment for sexually transmitted infections and access to contraception for women of childbearing potential.

In addition, young men should be offered medical male circumcision for health reasons.

But despite these options, we haven’t quite got to the point where we have been able to stop new infections, particularly among young people.

For young people, the daily decision to take a pill or use a condom or take a pill at the time of sexual intercourse can be very challenging.

HIV scientists and activists hope that young people may find that having to make this “prevention decision” only twice a year may reduce unpredictability and barriers.

For a young woman who struggles to get to an appointment at a clinic in a town or who can’t keep pills without facing stigma or violence, an injection just twice a year is the option that could keep her free of HIV.

What happens now?

The plan is that the Purpose 1 trial will go on but now in an “open label” phase. This means that study participants will be “unblinded”: they will be told whether they have been in the “injectable” or oral TDF or oral TAF groups.

They will be offered the choice of PrEP they would prefer as the trial continues.

A sister trial is also under way: Purpose 2 is being conducted in a number of regions including some sites in Africa among cisgender men, and transgender and nonbinary people who have sex with men.

It’s important to conduct trials among different groups because we have seen differences in effectiveness. Whether the sex is anal or vaginal is important and may have an impact on effectiveness.

How long until the drug is rolled out?

We have read in a Gilead Sciences press statement that within the next couple of months the company will submit the dossier with all the results to a number of country regulators, particularly the Ugandan and South African regulators.

The World Health Organization will also review the data and may issue recommendations.

We hope then that this new drug will be adopted into WHO and country guidelines.

We also hope we may begin to see the drug being tested in more studies to understand better how to incorporate it into real world settings.

Price is a critical factor to ensure access and distribution in the public sector where it is badly needed.

Gilead Sciences has said it will offer licences to companies that make generic drugs, which is another critical way to get prices down.

In an ideal world, governments will be able to purchase this affordably and it will be offered to all who want it and need protection against HIV.

[woodsfae]

During the randomised phase of the trial none of the 2,134 women who received lenacapavir contracted HIV. There was 100 percent efficiency. By comparison, 16 of the 1,068 women (or 1.5%) who took Truvada (F/TDF) and 39 of 2,136 (1.8%) who received Descovy (F/TAF) contracted the HIV virus.

[benihana-circumcision]

rhe doctor wasnt lying that descovy can gastrointestinal.distress

[log6]

anyone else feel terrible when they started descovy?

[hasdrubal-gisco]

June 20, 2024 – Gilead Sciences, Inc. today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the company’s twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, demonstrated 100% efficacy for the investigational use of HIV prevention in cisgender women. [...] PURPOSE 1, a Phase 3, double-blind, randomized study, is evaluating the safety and efficacy of twice-yearly, subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) and once-daily oral Descovy® (emtricitabine 200mg and tenofovir alafenamide 25mg; F/TAF) in more than 5,300 cisgender women and adolescent girls aged 16-25 across 25 sites in South Africa and three sites in Uganda. The drugs are being tested in parallel, with one group receiving twice-yearly lenacapavir and one group taking once-daily oral Descovy. Additionally, a third group was assigned once-daily oral Truvada. Study participants were randomized in a 2:2:1 ratio to lenacapavir, Descovy and Truvada, respectively. Because effective PrEP options already exist, there is broad consensus in the PrEP field that a placebo group would be unethical; thus, the trial used bHIV as the primary comparator and Truvada as a secondary comparator. There were 0 incident cases of HIV infection among 2,134 women in the lenacapavir group (incidence 0.00 per 100 person-years). There were 16 incident cases among 1,068 women in the Truvada group (incidence 1.69 per 100 person-years). The results demonstrated superiority of twice-yearly lenacapavir over bHIV (primary endpoint, incidence 2.41 per 100 person-years) and superiority of twice-yearly lenacapavir over once-daily Truvada (secondary endpoint), with p<0.0001 for both endpoints. In the trial, lenacapavir was generally well-tolerated and no significant or new safety concerns were identified. HIV incidence in the Descovy group was numerically similar (39 incident cases among 2,136 women, incidence 2.02 per 100 person-years) to that in the Truvada group and was not statistically superior to bHIV. Previous clinical trials among cisgender women have commonly found challenges with adherence to daily oral pills for PrEP, and adherence analyses for Descovy and Truvada from PURPOSE 1 are ongoing. In the trial, both Descovy and Truvada were generally well-tolerated and no new safety concerns were identified. 

[mcatmemoranda]

Descovy for PrEP

Adverse effects:

Worsening of hepatitis B (HBV) infection. Your healthcare provider will test you for HBV. If you have HBV and stop taking DESCOVY, your HBV may suddenly get worse. Do not stop taking DESCOVY without first talking to your healthcare provider, as they will need to check your health or give you HBV medicine.

Kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys before and during treatment with DESCOVY. If you develop kidney problems, your healthcare provider may tell you to stop taking DESCOVY.

Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat.

Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.

Every 3 months the pt needs to f/u for HIV test, CMP, lipid panel

[maleexperience-blog]

5

What's the point? Here it is: I started feeling sick about two days after. You know what came to mind...an HIV infection. Oh, I have a prescription for PrEP. I know the risks. I had not taken my PrEP in well over a week, because I hadn't been having sex. I took two tablets as soon as--we'll call him Big Bro--hit me up. So between the time I took a double dose of PrEP and the time he spermed me (fuck yea), only about an hour had passed. I couldn't tell you if that's enough time for the components of Descovy to deposit into my cells. Maybe. But you know how it goes (or do you?): when you feel desired, when a dude who can validate you gives himself to you, when you are the object of his erection...because let's face it: an erection to a man is more than an out for his sperm. No, his erection is comfort; it's safety; it's freedom to be. In the absence of any three, there is no erection.

So, yes, when you are the object of a man's erections and his affections, and it's the "right dude," the right dude who makes you feel validated, desired, affirmed...yea, so much goes out the window. Trust, I wasn't thinking much if at all about whether Descovy had bathed my rectal cells or even been absorbed beyond my stomach walls at that point. One *might* call this compulsive sexual behavior, one *might* call it sexual addiction, even. It can be either, I suppose, depending on your school of thought, but what it can also be? Is deprivation, of space, of freedom, of connection; and the need to utilize whatever time and space I have in this moment to connect in ways men are deprived. So what does this mean? 1) I should really take my PrEP more often; 2) I placed myself and my body at risk in exchange for a powerful, albeit fleeting, intimacy with the masculine spirit. Perceive that how you will, but take note nonetheless, that the power of the masculine spirit reconnecting with itself, is powerful. This wasn't no mating dance. I don't have female brain in a male body. We weren't making no baby, bro. We are two men, who seek the bond we are denied.

I am not sure if HIV is a reasonable space to go in my head, but is it really irrational? Given what disgust and shame we have inflicted on male-male intimacy? To think that after an encounter with a man, healthy looking or not, to think, somewhere in my mind, at whatever level of consciousness..."could it be HIV??" Looking at my symptoms now and the social / occupational contacts I've had, it seems more reasonable to assume I just have COVID; the new variant seems to have a GI element moreso than previous variants (I do have diarrhea pretty bad, smh...TMI, my bad). I'm taking PEP nonetheless. Fortunately I have access to some Biktarvy; *no*, I'm not advocating PEP as a leading solution to prevent HIV, nor am I touting it as even proven to be effective. *Studies are pending.* Shit, though, it's a tool nonetheless.

As much education as I have and as much as I know about HIV, its spread, its effects, its treatments, its progression from a death sentence 50 years ago to a manageable chronic condition today, the power of an intimate encounter still can shake my sensibilities. And honestly? some part of me is saying, "it's fucking worth it." I said what I said; you can read it again.

[virginpornstar]

SexxxPerTease Ep 247: My Partner Wants Me To Stop Taking PrEP

Follow me on all social media platforms!

[sanrio-inc]

I think I’m gonna stop taking Truvada. I’m just paranoid about my kidneys/organs. And I don’t have much sex anymore these days. And it’s less money and fewer pills I have to take. I’ll see if my insurance covers descovy but if not then I’ll just abstain from sex for a while. I haven’t really been in a sexual mood anyway. And maybe my kidneys are fine but it would be one fewer dead to worry about.

[teknolojihaber]

HIV'e karşı 0 etkili: Yeni ilaç, denemelerde olağanüstü sonuçlar gösteriyor

Uganda ve Güney Afrika'da yapılan 1. Aşama deneyi, HIV önleyici bir ilacın 0 başarı oranına sahip olduğunu buldu. Güney Afrika ve Uganda'da yapılan büyük bir klinik araştırmanın sonuçları, yeni bir profilaksi ilacının kadınlarda HIV enfeksiyonlarını şu anda mevcut olan diğer iki PrEP ilacından daha iyi önleyebileceğini gösteriyor. Faz 1 (Aşama 1) denemesi, bir füzyon kapsid inhibitörü olan Lenacapavir'i diğer iki HIV önleyici maddeye karşı değerlendirmek üzere 5.00 katılımcıyı taradı. The Conversation'ın bildirdiğine göre, altı aylık bir süre boyunca yılda iki kez Lenacapavir enjeksiyonunun diğer iki ilaca kıyasla 0 başarı oranı sağladığını buldular . Primedia Plus'ta konuşan GP Proaktif Sağlık Çözümleri CEO'su Dr. Fundile Nyati, "HIV'in önlenmesinde kesinlikle devrim yaratacak" dedi . Doktor-bilim adamı Linda-Gail Bekker liderliğindeki bir Gilead Sciences ekibi, Güney Afrika ve Uganda'daki 25 bölgede, üç PrEP ilacı olan HIV engelleyicilerin 5.000 kadındaki etkinliğini araştırdı. Geçen yıl 1,3 milyon yeni HIV enfeksiyonu bildirildi. Bu rakam önemli bir düşüşü yansıtsa da yine de hedefin üzerinde. Özellikle Güney Afrika'da HIV yaklaşık 8,45 milyon insanı etkiliyor. Uganda'da yaklaşık 1,2 milyon kişide HIV var, bu da Amerika Birleşik Devletleri'ndeki sayıya yakın. Ancak HIV, Güney Afrika ve Uganda'daki kadınlar için en yüksek riski oluşturuyor. Sorunu çözmek için araştırmacılar, ikisi şu anda kullanıma hazır olan üç PrEP ilacını test etti. The Conversation'a göre kadınlar, çift-kör denemede üç gruba ayrıldı; bu, katılımcıyı ve doktoru herhangi bir plasebo etkisine karşı koymak için hangi ilacın uygulandığını maskeledi. Birincisi, Afrika'daki kadınların çoğu, 16-25 yaşları arasındaki Truvada F/TDF kullanan günlük bir rejimin sürdürülmesini zor buluyor. Yeni PrEP çözümü Lenacapavir, yılda iki kez yapılacak enjeksiyonla sorunu ortadan kaldıracak. Ayrıca vücutta daha etkili şekilde dağılan Truvada'ya karşı daha yeni bir günlük hap olan Descovy F/TAF'ı da teste koydular . University World News'e göre genellikle yüksek gelirli ülkelerdeki trans erkek ve kadınlarda kullanılıyor . Primedia Plus , Pratisyen Hekim ve Proaktif Sağlık Çözümleri CEO'su Dr. Fundile Nyati'nin sözlerini şöyle aktardı: "Mevcut yöntemler işe yarasa da bazı zorluklarla karşılaşıyoruz." 0 başarı oranı Faz 1 çalışmasının sonuçları, Lenacapavir aşısı alan 2.134 kişinin HIV'e yakalanmadığını gösteriyor. Ancak iki günlük takviyeyi alan kadınlar bunu yaptı. The Conversation'ın haberine göre , 1.068 kişiden yaklaşık 16'sı Truvada'da virüse yakalandı ve 2.136 kadından 39'u Descovy'de HIV kaptı . Aşama 1 denemeleri, katılımcılara ne aldıklarının söyleneceği ve seçim hakkı tanınacağı kör olmayan testlere geçecektir. Diğer demografik özelliklerin , uyuşturucunun etkinliğini etkileyen cinsiyet türü olarak değerlendirileceği Amaç 2 denemesi de devam ediyor . Yeni çözümün, yetkililerin dünya çapındaki HIV enfeksiyonlarını 500.000 kişiye düşürme küresel hedefine ulaşmalarına yardımcı olacağını umuyoruz. Read the full article